Acticor Biotech SAS announced the first results of its ACTISAVE phase 2/3 study in the treatment of acute ischemic stroke. Analysis of the first results shows no evidence of efficacy for either the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) at 90 days after the stroke, or for the secondary endpoint, the proportion of patients with no disability (mRS 0-2) at 90 days. As a reminder, ACTISAVE (NCT05070260), an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study, evaluated the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke.

The study was deployed in the United States, Europe (8 countries), Israel and the United Kingdom. Glenzocimab is currently evaluated in two other clinical studies sponsored by academic teams: A Phase 2/3 GREEN study in stroke patients undergoing mechanical thrombectomy, with a futility analysis following the inclusion of the first 78 patients (30% of patients) expected in Fourth Quarter 2024. A phase 2b LIBERATE study in the treatment of myocardial infarction, with final results expected in Fourth Quarter 2025.